TY - JOUR
T1 - New strategies to prevent restenosis
AU - Kester, Mark
AU - Waybill, Peter
AU - Kozak, Mark
N1 - Funding Information:
This work was supported by National Institutes of Health Grant DK53715 and by the W.W. Smith Charitable Trust.
PY - 2001
Y1 - 2001
N2 - The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.
AB - The Holy Grail of cardiovascular pharmacology has been the search for an effective therapy targeting restenosis after angioplasty and/or intra-arterial stenting. The failure of promising therapeutics in clinical trials underscores the complexity and redundancy of the signaling cascades regulating mitogenesis and fibrogenesis. Novel therapeutic modalities have potential to target dysfunctional signaling elements directly in vascular smooth muscle cells. Significant progress in the treatment against restenosis will require the exploitation and cross-fertilization of developments in the fields of pharmacology, bioengineering, genetics, and molecular biology. Collaboration among researchers in these fields will be essential.
UR - http://www.scopus.com/inward/record.url?scp=0008455919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0008455919&partnerID=8YFLogxK
U2 - 10.2165/00129784-200101020-00001
DO - 10.2165/00129784-200101020-00001
M3 - Review article
C2 - 14728037
AN - SCOPUS:0008455919
SN - 1175-3277
VL - 1
SP - 77
EP - 83
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 2
ER -